Pfizer Inc Stock Fundamentals
| PFE Stock | 25.87 0.15 0.58% |
Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.
Pfizer |
Pfizer Inc Company Current Valuation Analysis
Pfizer's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pfizer Current Valuation | 289.72 B |
Most of Pfizer's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pfizer Inc has a Current Valuation of 289.72 B. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Pfizer Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pfizer competition to find correlations between indicators driving Pfizer's intrinsic value. More Info.Pfizer Inc is rated top company in current valuation category among its peers. It also is considered to be number one stock in price to book category among its peers . The ratio of Current Valuation to Price To Book for Pfizer Inc is about 88,768,456,768 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pfizer's earnings, one of the primary drivers of an investment's value.Pfizer Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in current valuation category among its peers.
Pfizer Fundamentals
| Current Valuation | 289.72 B | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 3.09 X | |||
| Revenue | 100.33 B | |||
| EBITDA | 41.03 B | |||
| Net Income | 31.37 B | |||
| Total Debt | 31.93 B | |||
| Cash Flow From Operations | 29.27 B | |||
| Price To Earnings To Growth | 1.19 X | |||
| Market Capitalization | 262.32 B | |||
| Total Asset | 197.21 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 197.21 B |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pfizer Stock Analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.